Skip to main content
NCBI home page
Thorax logoLink to Thorax
. 1976 Jun;31(3):265–270. doi: 10.1136/thx.31.3.265

An investigation of the chest radiographs in a controlled trial of busulphan, cyclophosphamide, and a placebo after resection for carcinoma of the lung.

H Stott, R Stephens, W Fox, G Simon, D C Roy
PMCID: PMC470416  PMID: 781905

Abstract

A standard series of radiographs of 588 patients allocated at random to treatment with busulphan (B patients), cyclophosphamide (C patients), or a placebo (P patients) for two years after surgery for bronchial carcinoma were viewed in three stages (following procedures which avoided bias) by an independent assessor, unaware of the allocated treatment of any patient, with a view to identifying pulmonary changes due to busulphan. Radiographic appearances consistent with busulphan lung were not reported in any of the 195 B patients (receiving a mean dosage of 464 mg of busulphan over 301 days) or of the 192 C patients but were present in one of the 201 patients receiving placebo.

Full text

PDF
265

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Batzenschlager A., Oberling F., Guerbaoui M., Vetter J. M. Fibrose pulmonaire mortelle avec léions cellulaires du poumon et du pancréas, attributées au busulfan. Arch Anat Pathol (Paris) 1972 Sep;20(3):291–294. [PubMed] [Google Scholar]
  2. Brynes R. K., Mostafavipour S. H., Fennessy J. J., Variakojis D. Diagnosis of busulfan lung by transcatheter biopsy. Chest. 1973 Dec;64(6):771–773. doi: 10.1378/chest.64.6.771. [DOI] [PubMed] [Google Scholar]
  3. Burns W. A., McFarland W., Matthews M. J. Busulfan-induced pulmonary disease. Report of a case and review of the literature. Am Rev Respir Dis. 1970 Mar;101(3):408–413. doi: 10.1164/arrd.1970.101.3.408. [DOI] [PubMed] [Google Scholar]
  4. Comhaire F., Van Hove W., Van Ganse W., Van der Straeten M. Busulphan and the lungs. Absence of lung function disturbance in patients treated with busulphan. Scand J Respir Dis. 1972;53(5):265–273. [PubMed] [Google Scholar]
  5. Comhaire F., Van der Straeten M., Van Hove W., Van Ganse W., Roels H. Longafwijkingen tijdens busulfan behandeling. Acta Tuberc Pneumol Belg. 1970;61(5):471–480. [PubMed] [Google Scholar]
  6. Etcheberry R., Becker P., Delmastro J., Donoso S. Fibrosis alveolar pulmonar por Myleran (Busulfán. Rev Med Chil. 1973 Jan;101(1):42–46. [PubMed] [Google Scholar]
  7. Feingold M. L., Koss L. G. Effects of long-term administration of busulfan. Report of a patient with generalized nuclear abnormalities, carcinoma of vulva, and pulmonary fibrosis. Arch Intern Med. 1969 Jul;124(1):66–71. doi: 10.1001/archinte.124.1.66. [DOI] [PubMed] [Google Scholar]
  8. GALTON D. A. Myleran in chronic myeloid leukaemia; results of treatment. Lancet. 1953 Jan 31;264(6753):208–213. doi: 10.1016/s0140-6736(53)90885-x. [DOI] [PubMed] [Google Scholar]
  9. Harrold B. P. Syndrome resembling Addison's disease following prolonged treatment with busulphan. Br Med J. 1966 Feb 19;1(5485):463–464. doi: 10.1136/bmj.1.5485.463. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Heard B. E., Cooke R. A. Busulphan lung. Thorax. 1968 Mar;23(2):187–193. doi: 10.1136/thx.23.2.187. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Jeanmart L., Klastersky J., Verhest A., Debusscher L., Potvliege P., Tagnon H., Tombroff M. Les pneumopathies diffuses au cours de la chimiotherapie par le busulfan et la bléomycine. J Belge Radiol. 1972 Jul-Aug;55(4):425–433. [PubMed] [Google Scholar]
  12. Kirschner R. H., Esterly J. R. Pulmonary lesions associated with busulfan therapy of chronic myelogenous leukemia. Cancer. 1971 May;27(5):1074–1080. doi: 10.1002/1097-0142(197105)27:5<1074::aid-cncr2820270511>3.0.co;2-g. [DOI] [PubMed] [Google Scholar]
  13. Kolarz G., Pietsehmann H., Regele H. Lungenveränderungen unter Busulphantherapie bei einem Fall von chronischer Myelose. Zentralbl Allg Pathol. 1970;113(5):539–544. [PubMed] [Google Scholar]
  14. Koss L. G., Melamed M. R., Mayer K. The effect of busulfan on human epithelia. Am J Clin Pathol. 1965 Oct;44(4):385–397. doi: 10.1093/ajcp/44.4.385. [DOI] [PubMed] [Google Scholar]
  15. LEAKE E., SMITH W. G. DIFFUSE INTERSTITIAL PULMONARY FIBROSIS AFTER BUSULPHAN THERAPY. Lancet. 1963 Aug 31;2(7305):432–434. doi: 10.1016/s0140-6736(63)92173-1. [DOI] [PubMed] [Google Scholar]
  16. Littler W. A., Kay J. M., Hasleton P. S., Heath D. Busulphan lung. Thorax. 1969 Nov;24(6):639–655. doi: 10.1136/thx.24.6.639. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Littler W. A., Ogilvie C. Lung function in patients receiving busulphan. Br Med J. 1970 Nov 28;4(5734):530–532. doi: 10.1136/bmj.4.5734.530. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Min K. W., Györkey F. Interstitial pulmonary fibrosis, atypical epithelial changes and bronchiolar cell carcinoma following busulfan therapy. Cancer. 1968 Nov;22(5):1027–1032. doi: 10.1002/1097-0142(196811)22:5<1027::aid-cncr2820220519>3.0.co;2-#. [DOI] [PubMed] [Google Scholar]
  19. NATHAN D. J., SANDERS M. Manifestations of acute leukemia in the parenchyma of the lung. N Engl J Med. 1955 May 12;252(19):797–801. doi: 10.1056/NEJM195505122521903. [DOI] [PubMed] [Google Scholar]
  20. OLINER H., SCHWARTZ R., RUBIO F., DAMESHEK W. Interstitial pulmonary fibrosis following busulfan therapy. Am J Med. 1961 Jul;31:134–139. doi: 10.1016/0002-9343(61)90229-7. [DOI] [PubMed] [Google Scholar]
  21. Smalley R. V., Wall R. L. Two cases of busulfan toxicity. Ann Intern Med. 1966 Jan;64(1):154–164. doi: 10.7326/0003-4819-64-1-154. [DOI] [PubMed] [Google Scholar]
  22. Woodliff H. J., Finlay-Jones L. R. Busulphan lung. Med J Aust. 1972 Sep 23;2(13):719–722. doi: 10.5694/j.1326-5377.1972.tb103507.x. [DOI] [PubMed] [Google Scholar]

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES